Kairos Pharma, LTD. (KAPA) stock
Close on Nov 13, 2026Market cap $1.69MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $1.69M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.44
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$6.39M
- EPS, diluted
- -$2.03
- Book value per share
- $1.16
- Diluted shares
- 3M
Trading
- Previous close
- $0.48
- Open
- $0.50
- Day's range
- $0.45 – $0.50
- Volume
- 12,571
- Average volume (20 days)
- 85,820
- Beta (5 years)
- 1.38
- 52-week range
- $0.42 – $7.28
- RSI (14 days)
- 27.1
- Volatility (1 year)
- 88.5%
- Relative volume
- 0.03×
- WACC
- 12.0%
Market cap history
Month-end market cap since 2024, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | KAPA | S&P 500 | Difference | KAPA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -45.3% | -3.0% | −42.2 pts | ||
| 3 months | -82.0% | -2.8% | −79.2 pts | ||
| Year to date | -90.9% | +11.5% | −102.4 pts | ||
| 1 year | -91.8% | +13.5% | −105.3 pts |
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Press releases
Releases Kairos Pharma filed with the SEC as exhibits to Form 8-K or 6-K
- News
- News
- News
- News
- Update
- Update
About Kairos Pharma
Pharmaceutical Preparations
Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company that advances therapeutics designed to overcome immune suppression and drug resistance in cancer patients. Its development pipeline includes antibodies, small molecules, and cell therapies targeting indications such as prostate cancer, lung cancer, breast cancer, and glioblastoma. The company's lead candidates include ENV 105, an antibody targeting CD105 to counter resistance in prostate and non-small cell lung cancers, and ENV 205, which targets extracellular mitochondrial DNA to address chemotherapy resistance. Its pipeline also features immunotherapeutic candidates such as KROS 101, an oral small-molecule GITR ligand modulator, and KROS 201, a dendritic-cell-activated T cell therapy for glioblastoma.
Company profile, executives and historyKairos Pharma stock: common questions
What is Kairos Pharma's stock price?
KAPA closed at $0.45 on Nov 13, 2026, down 5.62% on the day. Over the past 52 weeks it traded between $0.42 and $7.28.
What is Kairos Pharma's market cap?
Kairos Pharma was worth $1.69M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is KAPA's P/E ratio?
Kairos Pharma lost money over the twelve months to Sep 30, 2026 (diluted EPS -$2.03), so it has no meaningful P/E ratio.
Does Kairos Pharma pay a dividend?
No. Kairos Pharma has not paid a cash dividend over the last twelve months.
How has KAPA stock performed over the past year?
Including dividends, KAPA returned -91.8% over the past year, against +13.5% for the S&P 500.
Who are Kairos Pharma's competitors?
Companies most similar to Kairos Pharma by business, industry and size include PHIO, ORIC, CYDY, NWBO, BBOT.
See a number that looks wrong?